Cargando…
Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma
AIMS: This study aimed to (a) assess the effectiveness and safety of apatinib as a subsequent treatment for patients with sorafenib-resistant hepatocellular carcinoma (HCC), and (b) identify the clinical factors influencing their treatment outcomes. METHODS: The electronic medical records of consecu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378719/ https://www.ncbi.nlm.nih.gov/pubmed/32754228 http://dx.doi.org/10.1177/1758835920937422 |
_version_ | 1783562482832375808 |
---|---|
author | Zhang, Yingqiang Huang, Guihua Miao, Hongfei Song, Ze Zhang, Xiaoying Fan, Wenzhe Wang, Yu Li, Jiaping Chen, Yong |
author_facet | Zhang, Yingqiang Huang, Guihua Miao, Hongfei Song, Ze Zhang, Xiaoying Fan, Wenzhe Wang, Yu Li, Jiaping Chen, Yong |
author_sort | Zhang, Yingqiang |
collection | PubMed |
description | AIMS: This study aimed to (a) assess the effectiveness and safety of apatinib as a subsequent treatment for patients with sorafenib-resistant hepatocellular carcinoma (HCC), and (b) identify the clinical factors influencing their treatment outcomes. METHODS: The electronic medical records of consecutive patients with newly diagnosed advanced HCC treated with first-line sorafenib from 2015 to 2017 were retrospectively reviewed. Patients who were confirmed to have primary resistance to sorafenib were enrolled in this study. The outcomes of patients treated with apatinib were compared with those of patients who received supportive care. The primary endpoint was overall survival (OS). RESULTS: A total of 92 patients with sorafenib-resistant advanced HCC (84 men and 8 women; mean age, 51.9 years) were included. All patients had an etiology of hepatitis B. The median OS in the overall cohort was 5.0 months [95% confidence interval (CI): 3.9, 6.0]. Of 92 patients, 58 (63.0%) were treated with apatinib, and 34 (37.0%) received supportive care. Apatinib treatment was associated with longer survival times than supportive care for patients with sorafenib-resistant advanced HCC (median OS: 7.0 versus 4.0 months, p < 0.001). The results of the multivariate analysis demonstrated that liver tumor load [hazard ratio (HR): 3.653, 95% CI: 2.047, 5.965, p < 0.001] and extrahepatic spread (HR: 0.303, 95% CI: 0.231, 0.778, p = 0.003) were independent predictors of OS after apatinib treatment. CONCLUSION: This study showed that subsequent apatinib treatment may improve survival outcomes compared with supportive care for patients with sorafenib-resistant, advanced hepatitis B virus (HBV)-related HCC, especially for patients who have a lower liver tumor load and extrahepatic spread. |
format | Online Article Text |
id | pubmed-7378719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73787192020-08-03 Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma Zhang, Yingqiang Huang, Guihua Miao, Hongfei Song, Ze Zhang, Xiaoying Fan, Wenzhe Wang, Yu Li, Jiaping Chen, Yong Ther Adv Med Oncol Original Research AIMS: This study aimed to (a) assess the effectiveness and safety of apatinib as a subsequent treatment for patients with sorafenib-resistant hepatocellular carcinoma (HCC), and (b) identify the clinical factors influencing their treatment outcomes. METHODS: The electronic medical records of consecutive patients with newly diagnosed advanced HCC treated with first-line sorafenib from 2015 to 2017 were retrospectively reviewed. Patients who were confirmed to have primary resistance to sorafenib were enrolled in this study. The outcomes of patients treated with apatinib were compared with those of patients who received supportive care. The primary endpoint was overall survival (OS). RESULTS: A total of 92 patients with sorafenib-resistant advanced HCC (84 men and 8 women; mean age, 51.9 years) were included. All patients had an etiology of hepatitis B. The median OS in the overall cohort was 5.0 months [95% confidence interval (CI): 3.9, 6.0]. Of 92 patients, 58 (63.0%) were treated with apatinib, and 34 (37.0%) received supportive care. Apatinib treatment was associated with longer survival times than supportive care for patients with sorafenib-resistant advanced HCC (median OS: 7.0 versus 4.0 months, p < 0.001). The results of the multivariate analysis demonstrated that liver tumor load [hazard ratio (HR): 3.653, 95% CI: 2.047, 5.965, p < 0.001] and extrahepatic spread (HR: 0.303, 95% CI: 0.231, 0.778, p = 0.003) were independent predictors of OS after apatinib treatment. CONCLUSION: This study showed that subsequent apatinib treatment may improve survival outcomes compared with supportive care for patients with sorafenib-resistant, advanced hepatitis B virus (HBV)-related HCC, especially for patients who have a lower liver tumor load and extrahepatic spread. SAGE Publications 2020-07-23 /pmc/articles/PMC7378719/ /pubmed/32754228 http://dx.doi.org/10.1177/1758835920937422 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Zhang, Yingqiang Huang, Guihua Miao, Hongfei Song, Ze Zhang, Xiaoying Fan, Wenzhe Wang, Yu Li, Jiaping Chen, Yong Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma |
title | Apatinib treatment may improve survival outcomes of patients with
hepatitis B virus-related sorafenib-resistant hepatocellular
carcinoma |
title_full | Apatinib treatment may improve survival outcomes of patients with
hepatitis B virus-related sorafenib-resistant hepatocellular
carcinoma |
title_fullStr | Apatinib treatment may improve survival outcomes of patients with
hepatitis B virus-related sorafenib-resistant hepatocellular
carcinoma |
title_full_unstemmed | Apatinib treatment may improve survival outcomes of patients with
hepatitis B virus-related sorafenib-resistant hepatocellular
carcinoma |
title_short | Apatinib treatment may improve survival outcomes of patients with
hepatitis B virus-related sorafenib-resistant hepatocellular
carcinoma |
title_sort | apatinib treatment may improve survival outcomes of patients with
hepatitis b virus-related sorafenib-resistant hepatocellular
carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378719/ https://www.ncbi.nlm.nih.gov/pubmed/32754228 http://dx.doi.org/10.1177/1758835920937422 |
work_keys_str_mv | AT zhangyingqiang apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT huangguihua apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT miaohongfei apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT songze apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT zhangxiaoying apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT fanwenzhe apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT wangyu apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT lijiaping apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma AT chenyong apatinibtreatmentmayimprovesurvivaloutcomesofpatientswithhepatitisbvirusrelatedsorafenibresistanthepatocellularcarcinoma |